Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 2,506 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal protein Clear all
Completed Phase 2 Interventional

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

NCT00063310
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Leuprolide acetate
Drug
Lead sponsor
Voyager Pharmaceutical Corporation
Industry
Eligibility
65 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Sun City, Arizona • Fort Lauderdale, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 30, 2026, 6:35 AM EDT
Terminated Phase 2 Interventional Results available

Abraxane/Bevacizumab

NCT01821859
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer
Interventions
Abraxane, Bevacizumab
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT07097259
View directory record Official record
Conditions
Hypogonadism
Interventions
Test: Follitropin alfa, Reference: Follitropin alfa, Zoladex
Combination Product · Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 30, 2026, 6:35 AM EDT
Completed No phase listed Observational

Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma

NCT01609803
View directory record Official record
Conditions
Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 30, 2026, 6:35 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

NCT04282174
View directory record Official record
Conditions
Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions
CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine
Device · Procedure · Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
Up to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

NCT01888497
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin, Diphenhydramine citrate, Triazolam, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
25 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
4
States / cities
South Miami, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 30, 2026, 6:35 AM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

NCT00003920
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cyclosporine, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody m170, yttrium Y 90 monoclonal antibody m170
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)

NCT01764711
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Cosyntropin administration
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

NCT03082534
View directory record Official record
Conditions
HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer, Nasopharynx Cancer, Sinonasal Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab, Cetuximab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

NCT00723099
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Indolent Non-Hodgkin Lymphoma, Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Procedure · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 69 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
6
States / cities
Aurora, Colorado • Denver, Colorado • Salt Lake City, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle

NCT02578771
View directory record Official record
Conditions
Surgical Site Infection
Interventions
ZuraPrep with 70% IPA, ZuraPrep without 70% IPA, ChloraPrep CHG/IPA Teal Tint, Normal Saline
Drug · Other
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sterling, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 30, 2026, 6:35 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

NCT00008307
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, syngeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 30, 2026, 6:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fat Metabolism in OSA and COPD

NCT02157844
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Obesity
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 30, 2026, 6:35 AM EDT
Recruiting Phase 1 Interventional

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 6:35 AM EDT
Terminated Phase 2 Interventional Results available

Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)

NCT00252239
View directory record Official record
Conditions
Stroke
Interventions
tenecteplase, tissue plasminogen activator, tPA
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
San Diego, California • Englewood, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 1 Interventional

Pulse ACTH vs. MP for MS

NCT01049451
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTH, Methylprednisolone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protein-Prebiotic Wellbeing Study

NCT05303753
View directory record Official record
Conditions
Digestive Health, Quality of Life
Interventions
fermented dairy protein with prebiotic fiber
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 35 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)

NCT02623829
View directory record Official record
Conditions
Post-operative Excessive Scarring
Interventions
Botulinum Toxin, Saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 30, 2026, 6:35 AM EDT
Recruiting Phase 4 Interventional

Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing

NCT07326553
View directory record Official record
Conditions
Diabete Mellitus, Foot Ulcer Chronic
Interventions
Placental Membrane
Biological
Lead sponsor
BioXTek
Industry
Eligibility
45 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 30, 2026, 6:35 AM EDT
Terminated Phase 2 Interventional Results available

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

NCT00354172
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI)
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

NCT01200329
View directory record Official record
Conditions
Lymphoma
Interventions
Gemcitabine, Busulfan, Melphalan, Stem Cell Transplantation, Palifermin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

NCT00054756
View directory record Official record
Conditions
Healthy, Pituitary Disease, Thyroid Disease
Interventions
TRH (Thyrotropin Releasing Hormone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 30, 2026, 6:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers

NCT00234156
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
oral fructose and high fat diet
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 30, 2026, 6:35 AM EDT